IMT for Primary Clostridium Difficile Infection
IMT for Primary Clostridium Difficile Infection
This is a randomized controlled trial to compare the effect of a 10-day course of per oral
 metronidazole versus a one-time rectal instillation of an anaerobically cultivated human
 intestinal microbiota for the treatment of a first occurrence of Clostridium difficile
 infection (CDI). Recurrent CDI is common after standard antibiotic treatment. We hypothesize
 that the instillation of a healthy intestinal microbiota will be more effective in inducing a
 durable cure than metronidazole for primary CDI.
Up to one third of patients with clostridium difficile infection treated with antibiotics
 experience recurrent or relapsing symptoms within a few weeks. Even with subsequent
 antibiotic treatment, multiple recurrences/relapses are frequent. Fecal microbiota
 transplantation (FMT) has been shown to be significantly more effective in curing recurrent
 CDI than repeated antibiotic treatment. In current guidelines, FMT is proposed as a treatment
 option after multiple recurrences/relapses of CDI. The rationale to reserve transplantation
 of donor feces for recurrent and difficult cases of CDI is a possible risk of pathogen
 transmittance and the cumbersome and costly process of finding a donor and screen for
 communicable disease. The effect of FMT for recurrent CDI, however, suggests that this
 therapy may be more effective than antibiotics in inducing a durable cure also for primary
 CDI.

 We aim to use an anaerobically cultivated human intestinal microbiota (ACHIM) that has been
 extensively tested for pathogens, from a donor screened for communicable diseases, to avoid
 the need for a case-by-case donor screening. The term Intestinal Microbiota Therapy (IMT)
 will be used to describe the ACHIM treatment.

 Patients with a first occurrence of CDI defined by diarrhea, as defined by the World Health
 Organization, and a positive stool test for toxigenic Clostridium difficile will be
 randomized 1:1 to either a 10-day course of metronidazole 400 mg t.i.d. or a rectal
 instillation of 60 ml ACHIM suspension.

 Patients will be contacted on day 4 by an unblinded study investigator and on days 35 and 70
 by a blinded study investigator to evaluate the treatment effect. In addition, the patients
 will register the frequency of bowel movements on days 1-4, 7, 14 and 21.

 In the case of clinical deterioration, appropriate measures will be undertaken according to
 current guidelines.

 A second instillation of ACHIM suspension will be considered on day 4 in the absence of
 clinical improvement.

 The primary endpoint is the rate of primary cure from CDI and no sign of relapse/recurrence
 within 70 days, or persistent diarrhea that could be explained by other causes with three
 consecutive negative stool tests for toxigenic Clostridium difficile.

 Treatment failure is defined as persistent diarrhea with a positive stool test for toxigenic
 Clostridium difficile.

 Relapsing or recurrent CDI is defined as diarrhea and a positive stool test for toxigenic
 Clostridium difficile within 70 days of treatment initiation after an initial resolution of
 diarrhea.

 Preliminary sample size is estimated from a hypothesis of a primary cure rate without
 recurrence within 70 days of 75 % with metronidazole vs. 87.5 % with IMT.

 An interim analysis is planned after inclusion of the first 40 patients to guide the final
 sample size estimation.

 Patients will be recruited at six hospitals in South-East Norway.

 Before the start of the pilot phase, an independent data safety and monitoring board (DSMB)
 was established to monitor potential adverse events, and to advise the study team on the
 results of the pilot phase of the trial with regard to benefits and harms of the treatment,
 recruitment, and organization.

 We recognized a slower than anticipated recruitment during the pilot phase of the trial. The
 slow recruitment was due to the current clinical practice of rapid initiation of antibiotic
 therapy by clinicians, before the trial team could ascertain eligible patients for enrolment.

 After the inclusion of 20 eligible patients with concluded follow-up in January 2018, the
 DSMB met with the trial investigators on January 29 (2018), to discuss the results of the
 pilot phase. In light of the results, the DSMB recommended to start preparations for the main
 phase of the trial to validate the magnitude of the effects of FMT in primary CDI. Further,
 due to the nature of the results of the pilot and its potential implications on clinical
 practice, the DSMB recommended publication of the pilot data. This was also deemed necessary
 for adequate recruitment of the main trial.
Inclusion Criteria:

 -  Diarrhea as defined by the World Health Organization (passage of 3 or more loose or
 liquid stools (i.e. taking the shape of the receptacle or corresponding to Bristol
 stool chart types 5-7) per day, or more frequently than is normal for the individual,
 and

 -  Positive fecal test for toxigenic Clostridium difficile, and

 -  No evidence of CDI during the previous year.

 Exclusion Criteria:

 -  Known presence of other stool pathogens known to cause diarrhea.

 -  Pregnancy and nursing.

 -  Patients with ongoing antibiotic treatment for other infections that cannot be stopped
 for at least 12 hours.

 -  Inflammatory bowel disease.

 -  Patients incapable of providing informed consent.

 -  Patients with <3 months life expectancy.

 -  Serious immunodeficiency caused by chemotherapy or other medication.

 -  Active immunocompromising disease.

 -  Patients unable to comply with protocol requirements.

 -  Patients in need of intensive care who are American Society of Anesthesiologists (ASA)
 Physical Status classification IV and V.

 -  Known hypersensitivity to Metronidazole